Notation to File

NOTE TO THE FILE

SERIAL NUMBER:            90517616

DATE:                                09/09/2021

NAME:                               cnodes

NOTE:         

Searched:                                                             
     Google                            
     Lexis/Nexis                       
     OneLook
     Wikipedia
     Acronym Finder                         Protest evidence reviewed
     Other:

Checked:                                                             
     Geographic significance          
     Surname                          
     Translation
     ID with ID/CLASS mailbox

     Checked list of approved Canadian attorneys and agents

Discussed file with
Attorney/Applicant via:
        phone                               Left message with
    X   email                               Attorney/Applicant

     Requested Law Library search       X   Issued Examiner’s Amendment
     for:                                   and entered changes in TRADEUPS

        PRINT        DO NOT PRINT           Added design code in TRADEUPS
     Description of the mark
     Translation statement                  Re-imaged standard character
                                            drawing
     Negative translation statement             
     Consent of living individual           Contacted TM MADRID ID/CLASS
                                            about misclassified definite ID
     Changed TRADEUPS to:

     OTHER:

 

From: Dubow, Rachelle A. <rachelle.dubow@morganlewis.com>
Sent: Thursday, September 9, 2021 6:19 PM
To: Nodes, Christopher <Christopher.Nodes@USPTO.GOV>
Cc: Byrne, Peter G. <peter.byrne@morganlewis.com>; Kagan, Jennifer A. <jennifer.kagan@morganlewis.com>; Washington Trademark Docket <trademark@morganlewis.com>
Subject: RE: Trademark Application for Serial No. 90517616 - SALIOGASE

 

CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before responding, clicking on links, or opening attachments.

 

Christopher –

 

Thank you for your message.  Can you please make the following amendments:

 

 

Please amend the ID in Class 1 as follows: “Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research” in Class 1

 

Pharmaceutical preparations for genetically driven disorders, neurological, gastrointestinal, metabolic, immunological,  dyslipidemias musculoskeletal, oncological disorders and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes", in Class 5.

 

Many thanks,

 

Rachelle

 

 

Rachelle A. Dubow

Morgan, Lewis & Bockius LLP

One Federal Street | Boston, MA 02110-1726

Direct: +1.617.951.8939 | Main: +1.617.341.7700 | Fax: +1.617.341.7701

rachelle.dubow@morganlewis.com | www.morganlewis.com

Pronouns: She/Her/Hers

 

Assistant: Pernashee S. Dave | +1.617.341.7551 | pernashee.dave@morganlewis.com

 

From: Nodes, Christopher <Christopher.Nodes@USPTO.GOV>
Sent: Tuesday, September 7, 2021 9:52 AM
To: Washington Trademark e-Filings <trademarks@morganlewis.com>
Cc: Dubow, Rachelle A. <rachelle.dubow@morganlewis.com>; Estell, Brittany A. <brittany.estell@morganlewis.com>; Kagan, Jennifer A. <jennifer.kagan@morganlewis.com>
Subject: Trademark Application for Serial No. 90517616 - SALIOGASE

 

[EXTERNAL EMAIL]

Dear Ms. Dubow,

 

For U.S. Trademark Application No. 90517616,  there is one small issue that can be corrected without the need for an Office Action.

 

Identification of Goods Requirement 

 

We require an amended identification of the goods and because the wording “samples of nucleotide sequence variants and modifications” is indefinite.  Further, the wording “Pharmaceutical preparations” is indefinite and must be modified to specify the disease or condition treated or prevented. 

 

The following amended Identification is suggested, if accurate, with changes in bold:

 

“Reagents, nucleic acids, and nucleotides for scientific and research use in the fields of clinical research, drug development, agriculture and genetics research; reagent kits comprised of reagents and chemical preparations for scientific research purposes; samples of nucleotide sequence variants and modified nucleotide sequences for use in the fields of scientific research, clinical research, and scientific diagnostics research” in Class 1

 

“Pharmaceutical preparations for hypercholesterolemia, macular degeneration, and diseases of the retina, liver, heart, lung, bone marrow, and kidney; Reagents, nucleic acids, and nucleotides for medical and veterinary purposes” in Class 5

 

Please let me know by close of business on Friday, Sept. 10 if you approve of my amending the identification as described.  If you agree, I can make the changes for you via Examiner’s Amendment, and the application may proceed toward registration.  If I don’t hear from you, I will issue an Office Action.

 

Best regards,

 

Christopher J Nodes

Examining Attorney

Law Office 116

(571) 272-5220

christopher.nodes@uspto.gov

 

DISCLAIMER
This e-mail message is intended only for the personal use
of the recipient(s) named above. This message may be an
attorney-client communication and as such privileged and
confidential and/or it may include attorney work product.
If you are not an intended recipient, you may not review,
copy or distribute this message. If you have received this
communication in error, please notify us immediately by
e-mail and delete the original message.